SEC Form SC 13G filed by Alto Neuroscience Inc.

11/12/24 9:50:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANRO alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ALTO NEUROSCIENCE INC COMMON STOCK Cusip #02157Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #02157Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,362,697 Item 6: 0 Item 7: 2,363,056 Item 8: 0 Item 9: 2,363,056 Item 11: 8.765% Item 12: HC Cusip #02157Q109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,363,056 Item 8: 0 Item 9: 2,363,056 Item 11: 8.765% Item 12: IN Item 1(a). Name of Issuer: ALTO NEUROSCIENCE INC Item 1(b). Address of Issuer's Principal Executive Offices: 650 CASTRO STREET, SUITE 450 MOUNTAIN VIEW, CA 94041 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 02157Q109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,363,056 (b) Percent of Class: 8.765% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,363,056 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALTO NEUROSCIENCE INC. No one other person's interest in the COMMON STOCK of ALTO NEUROSCIENCE INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALTO NEUROSCIENCE INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ANRO alert in real time by email

Recent Analyst Ratings for

$ANRO

Date	Price Target	Rating	Analyst
10/23/2024	$29.00 → $4.00	Outperform → Neutral	Wedbush
10/23/2024		Buy → Neutral	Rodman & Renshaw
9/3/2024	$29.00	Outperform	Wedbush
2/27/2024		Outperform	William Blair
2/27/2024		Outperform	TD Cowen
2/27/2024	$32.00	Outperform	Robert W. Baird
2/27/2024	$33.00	Buy	Jefferies
2/27/2024	$32.00	Buy	Stifel

More analyst ratings

SEC Form SC 13G filed by Alto Neuroscience Inc.

11/12/24 9:50:14 AM ET

$ANRO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANRO alert in real time by email

Recent Analyst Ratings for

$ANRO

Date	Price Target	Rating	Analyst
10/23/2024	$29.00 → $4.00	Outperform → Neutral	Wedbush
10/23/2024		Buy → Neutral	Rodman & Renshaw
9/3/2024	$29.00	Outperform	Wedbush
2/27/2024		Outperform	William Blair
2/27/2024		Outperform	TD Cowen
2/27/2024	$32.00	Outperform	Robert W. Baird
2/27/2024	$33.00	Buy	Jefferies
2/27/2024	$32.00	Buy	Stifel

More analyst ratings

SEC Form SC 13G filed by Alto Neuroscience Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ANRO

SEC Form SC 13G filed by Alto Neuroscience Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ANRO

$ANRO
Insider Purchases

CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

$ANRO
Press Releases

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

$ANRO
Insider Trading

SEC Form 4 filed by Director Sanchez Ramiro

SEC Form 3 filed by new insider Sanchez Ramiro

SEC Form 4 filed by CHIEF OPERATING OFFICER Hanley Jr. Michael Conick

$ANRO
Analyst Ratings

Alto Neuroscience downgraded by Wedbush with a new price target

Alto Neuroscience downgraded by Rodman & Renshaw

Wedbush initiated coverage on Alto Neuroscience with a new price target

$ANRO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

SEC Form 10-Q filed by Alto Neuroscience Inc.

Alto Neuroscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

$ANRO
Leadership Updates

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Christopher Nixon Cox Named Chairman of High-Trend International Group

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

$ANRO
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.